Literature DB >> 7551410

Rhinovirus infection of the normal human airway.

J M Gwaltney1.   

Abstract

Selected events in rhinovirus infection of the normal human airway can be regarded as occurring sequentially. Initial steps in rhinovirus pathogenesis are believed to include viral entry into the nose, mucociliary transport of virus to the posterior pharynx, and initiation of infection in ciliated and non-ciliated epithelial cells of the upper airway. Viral replication peaks on average within 48 h of initiation of infection and persists for up to 3 wk. Infection is followed by activation of several inflammatory mechanisms, which may include release or generation of interleukins, bradykinins, prostaglandins, and possibly histamine and stimulation of parasympathetic reflexes. Pathophysiologic processes are initiated, which include vasodilatation of nasal blood vessels, transudation of plasma, glandular secretion, and stimulation of nerve fibers, causing pain and triggering sneeze and cough reflexes. The resultant clinical illness is a rhinosinusitis, pharyngitis, and bronchitis, which, on average, lasts 1 wk.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551410     DOI: 10.1164/ajrccm/152.4_Pt_2.S36

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  11 in total

1.  The rhinovirus type 14 genome contains an internally located RNA structure that is required for viral replication.

Authors:  K L McKnight; S M Lemon
Journal:  RNA       Date:  1998-12       Impact factor: 4.942

2.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

3.  Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

Authors:  A D Smith; S C Geisler; A A Chen; D A Resnick; B M Roy; P J Lewi; E Arnold; G F Arnold
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Biochemical and genetic studies of the initiation of human rhinovirus 2 RNA replication: purification and enzymatic analysis of the RNA-dependent RNA polymerase 3D(pol).

Authors:  K Gerber; E Wimmer; A V Paul
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Biochemical and genetic studies of the initiation of human rhinovirus 2 RNA replication: identification of a cis-replicating element in the coding sequence of 2A(pro).

Authors:  K Gerber; E Wimmer; A V Paul
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management of the common cold.

Authors:  Mostafa Yakoot; Amel Salem
Journal:  Int J Gen Med       Date:  2011-01-12

7.  Canadian guidelines for rhinosinusitis: practical tools for the busy clinician.

Authors:  Shaun Kilty
Journal:  BMC Ear Nose Throat Disord       Date:  2012-02-01

8.  A placebo-controlled trial of Korean red ginseng extract for preventing influenza-like illness in healthy adults.

Authors:  Ki-Chan Ha; Min-Gul Kim; Mi-Ra Oh; Eun-Kyung Choi; Hyang-Im Back; Sun-Young Kim; Eun-Ok Park; Dae-Young Kwon; Hye-Jeong Yang; Min-Jeong Kim; Hee-Joo Kang; Ju-Hyung Lee; Kyung-Min Choi; Soo-Wan Chae; Chang-Seop Lee
Journal:  BMC Complement Altern Med       Date:  2012-02-08       Impact factor: 3.659

9.  Rapid multiserotype detection of human rhinoviruses on optically coated silicon surfaces.

Authors:  R Ostroff; A Ettinger; H La; M Rihanek; L Zalman; J Meador; A K Patick; S Worland; B Polisky
Journal:  J Clin Virol       Date:  2001-05       Impact factor: 3.168

Review 10.  Evaluation of echinacea for treatment of the common cold.

Authors:  J T Giles; C T Palat; S H Chien; Z G Chang; D T Kennedy
Journal:  Pharmacotherapy       Date:  2000-06       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.